Cita APA (7a ed.)

NG, A., RM, A., AA, A., M, A., R, K., H, A., & AA, A. (2021). Aflibercept versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema. Dove Medical Press.

Cita Chicago Style (17a ed.)

NG, Alsaedi, Alselaimy RM, Alshamrani AA, AlAjmi M, Khandekar R, Al-Dhibi H, y Al-Abdullah AA. Aflibercept Versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema. Dove Medical Press, 2021.

Cita MLA (8a ed.)

NG, Alsaedi, et al. Aflibercept Versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema. Dove Medical Press, 2021.